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Much of the current understanding in hematopoietic stem cell differentiation into immune-cell
lineages comes from mouse studies, but how well does it translate to the human system?The pathways through which hemato-
poietic stem cells (HSCs) generate lin-
eage-committed progenitors and ulti-
mately the mature cells of the blood
and immune system have been pro-
gressively defined during more than
40 years of investigation. Most of the
fundamental concepts on which we
base our understanding of hematopoi-
etic differentiation have relied on the
analysis of specific murine mutants
and/or the use of experimental murine
transplantation models. The power
and elegance of these experimental
models have allowed a progressively
more-detailed dissection of murine
lymphohematopoietic development;
however, comparatively few similar
studies exist in humans.
The reasons for the predominance
of murine over human studies in hema-
topoiesis and immunology have been
technical, logistical, and ethical. The
ability to manipulate the expression
of single genes in the mouse allows
targeted gain- and loss-of-function
studies within the developing animal,
often leading to well-defined, mecha-
nistic conclusions. Competitive-repo-
pulation models allow quantitation
of murine stem and progenitor cells
with defined patterns of repopulation.
Within each inbred murine strain, data
are highly reproducible, a stark con-
trast to the marked variability inherent
in immunophenotypic and functional
studies with human cells. It should be
noted, however, that substantial dif-
ferences in immunophenotype and
function can be seen between murine
strains (de Haan et al., 2000; Span-
grude and Brooks, 1992). It is hardly
surprising then, that even greater bio-674 Immunity 26, June 2007 ª2007 Elselogical differences exist between mu-
rine and human species.
Species differences range from
detailed technical considerations to
fundamental biological processes. Im-
munophenotypic differences between
mice and humans are particularly strik-
ing in the study of hematopoietic stem
and progenitor cells. For example, with
the exception of a rare subset, the
majority of human HSCs express the
CD34 antigen; further fractionation of
CD34+ cells reveals that lineage com-
mitment and loss of generative and
repopulating capacity are marked by
the onset of CD38 expression (Hao
et al., 1996; Larochelle et al., 1996;
Terstappen et al., 1991). In contrast,
the expression of CD34 and CD38 is
reversed inmurinehematopoiesis,with
long-term repopulating capacity con-
tained within the CD34CD38+ subset
and short-term repopulation in the
CD34+CD38 subset (Osawa et al.,
1996; Randall et al., 1996).
Functional proof of a HSC popula-
tion is generally accepted to require
the use of a transplantation model that
allows long-term engraftment of cells
with full lymphohematopoietic poten-
tial. In murine studies, this is most of-
ten accomplished by competitive re-
population of donor cells into lethally
irradiated congenic hosts. The use of
xenogeneic in vivo models to study
engraftment and differentiation of iso-
lated human cells, although consid-
ered the gold standard for human
HSC studies, has obvious limitations.
The most commonly used model for
human studies, the NOD-Scid im-
mune-deficient mouse, generates pre-
dominantly B cell progenitors, withvier Inc.little myeloid and no T cell engraft-
ment. It is assumed that the lineage
skewing seen in this, as well as the re-
lated NOD-SCID-b2-microglobulin-de-
ficient mouse, is from selective lineage
differentiation due to incomplete spe-
cies cross-reactivity of signals from
the microenvironment. It is also possi-
ble that these models have selective
defects in the type of human cells
able to home and engraft successfully.
Recently described models with
more-profoundblocks in thymopoiesis,
such as the Rag2 and IL2Rg double-
deficient mouse and the NOD-SCID
IL2Rg-deficient mouse, provide an en-
vironment for more-complete lineage
(including T lymphoid) differentiation
for human cells and have substantially
extended the kinds of questions in-
vestigators can now ask in vivo with
human cells. Nevertheless, it remains
unclear exactly how each of these
immune-deficient xenogeneic models
reflects the biology either revealed by
the assays of congenic murine trans-
plant or seen in the clinical bone mar-
row (BM) transplantation setting. An
example of such confusion is how
long-term versus short-term repopula-
tion should be defined in xenogeneic
models, a concept that is one of the
classic tests for assigning stem versus
progenitor status. Can we necessarily
expect a human HSC to exhibit normal
clonal activation and self-renewal pat-
terns in a mouse environment?
The logistical and regulatory difficul-
ties in obtaining human tissue for re-
search also act to discourage such
studies. Largely as a response to this
problem, umbilical cord blood, which
is discarded as waste after most
Immunity
CommentariesFigure 1. Reciprocal Expression of CD34 and CD38 between Human andMurine Stem
and Lymphoid Progenitors
In humans, CD34 is expressed on both HSCs (LTRC, long-term repopulating cells; and STRC,
short-term repopulating cells) and lymphoid progenitors. A subset of cord-blood CLPs does not
express either CD38 or IL-7Ra; these appear to be the precursors of CD38+ CLPs in CB. No
such CD38 CLP exists in human BM, i.e., CD38 is expressed on all BM CLPs. No phenotype
has yet been defined that discriminates between human STRC and LTRC. CD34 and CD38
expression on murine CLP has not been reported.deliveries and can be collected from
donors without risk or discomfort,
has become the predominant tissue
source for the study of human hemato-
poietic stem and progenitor biology.
However, similar cautions as those
described above should be exercised
in extrapolating data from one human
hematopoietic source to another. The
potential confusion this can cause is
illustrated in more detail in two exam-
ples that involve IL-7 regulation of
lymphopoiesis: the identification of the
early stages of lymphoid commitment
and the role of IL-7 in B lymphopoiesis.
For many years, lymphoid and mye-
loid cells have been assumed to be
generated from the hematopoietic
stem cell through mutually exclusive
pathways of differentiation that pass
initially through either the common
lymphoid progenitor (CLP) or a mye-
loid-erythoid progenitor, respectively.
The murine CLP was identified in
1997 by Kondo et al., using expression
of the IL-7 receptor a (IL-7Ra) to mark
lymphoid-restricted progenitors withinthe Sca-1lo, Thy-1ckitlo, lin popula-
tion of BM (Kondo et al., 1997). This
finding fit well with the known pheno-
type of IL-7Ra-deficient mice, i.e., a
lack of B, T, and natural killer (NK) cells
in combination with normal HSC
function and myeloid differentiation.
Two years earlier, Galy et al. (1995)
had identified in the human BM a
CD34+linCD10+population that satis-
fied the criteria of CLP, i.e., full lym-
phoid (T, B, and NK) but no myeloid or
erythroid differentiation potential; the
expression of IL-7Ra on the CD10+
CLP in thehumanBMwasnot explored
at that time. However, more recently
a primitive multilymphoid (B, NK, and
recently T cell) progenitor was identi-
fied in human umbilical cord blood,
on the basis of expression of CD7 on
a subpopulation of CD34+CD38 cells
(Hao et al., 2001; Hoebeke et al.,
2007). In contrast to the murine CLP,
this CD34+CD38CD7+ cord-blood
progenitor does not express IL-7Ra.
One hypothesis from these findings is
that IL-7 acts at the CLP stage inImmunitmurine, but not human lymphopoiesis,
a theory that would fit with the finding
that children born with mutations in
IL-7R, either in the ligand binding (a)
chain or the signaling (g) domain,
have less-severe lymphoid defects
than mice with similar mutations (B
cell numbers are normal) (Fischer
et al., 2005). However, it should be
noted that the CD34+CD38CD7+ im-
munophenotype of cord blood is not
found in BM. The previously described
CD34+LinCD10+ lymphoid-restricted
population in human BM expresses
CD38 and is in fact heterogeneous,
including both CD7+ B andNK cell pro-
genitors and CD7 B cell progenitors
(Rossi et al., [2003] and G.M.C., un-
published data) (Figure 1). The expres-
sion of IL-7Ra on human CLP from BM
would be a more-relevant comparison
with the murine studies, but has not
yet been elucidated.
The potential for confusion in over-
laying data from different stages of on-
togeny and from different species is
also seen in studies of IL-7 and B cell
differentiation. Human B cell produc-
tion has long been thought to differ
from that in the mouse with respect
to the requirement for IL-7 (Milne and
Paige, 2006). Initial data from in vitro
models of murine B cell production
and from IL-7- and IL-7Ra-deficient
mice indicated that B cell production
in the mouse is dependent on IL-7.
Subsequent experiments showed
that fetal and neonatal B cell produc-
tion was spared in mice with IL-7 de-
fects, providing evidence that murine
B cell production at early points in
ontogeny was not dependent on IL-7
(Milne and Paige, 2006). This finding
was important because the assess-
ments of patients with IL-7R signaling
defects (TNKB+) asdescribedabove
occurred in newborns or very young
children. In addition, the initial in vitro
studies of human B cell development
relied on fetal BM as a hematopoietic
source. Thus, initial conclusions about
differences in mouse and human B cell
development were based on compari-
sons of adult murine B cell production
and fetal or neonatal human B lympho-
poiesis. It is possible that at least some
of the differences in B cell develop-
ment that have been attributed to
evolutionary differences between they 26, June 2007 ª2007 Elsevier Inc. 675
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are due to differences in fetal and adult
B lymphopoiesis.
More-recent studies of in vitro hu-
man B cell development have used
CB and adult BM as hematopoietic
sources. However, these studies em-
ployed cocultures that included mu-
rine stromal-cell lines that have been
selected for their ability to support
mouse B lymphopoiesis. These cell
lines produce high amounts of murine
IL-7 (Johnson et al. [2005] and K.J.P.
et al., unpublished data), and, contrary
to initial reports, murine IL-7 has now
been shown to stimulate human IL-7R
signaling (Johnson et al., 2005). Thus,
the requirement for exogenous human
IL-7 and its effects on human B cell de-
velopment have likely been obscured
in most studies to date. Experiments
using a human stromal-cell coculture
model are providing evidence that in
humans, as in mice, the production B
cells from adult BM is dependent on
IL-7 (K.J.P. et al., unpublished data).
If B cell production in adult humans
is dependent on IL-7, as it is in the
mouse, it will be important to deter-
mine whether IL-7 plays identical roles
and targets similar B cell precursor
populations at equivalent points in
ontogeny in both species. Studies by
Hardy et al. (Hardy et al., 1991) with
subsequent refinements and exten-
sions have correlated immunoglobulin
gene rearrangement and intracellular-
protein expression with changes in
surface-marker expression during
mouse B cell differentiation. The re-
sulting model of B cell development
that identified precisely defined, devel-
opmentally sequential populations of
B lineage cells on the basis of surface
immunophenotype became the stan-
dard used in assessing B cell develop-
ment in genetically engineered mice.
This model provided a valuable tool
because it allowed not only the identi-
fication, but also the isolation of living
B lineage cells at precise points in dif-
ferentiation. Isolated precursors could
then be assessed for transcription-
factor expression or function, or they
could be placed in culture so that sub-
sequent stages of development could
be examined. A number of human
studies have identified a variety of sur-
face markers that are helpful in identi-676 Immunity 26, June 2007 ª2007 Elsevfying progressive stages in human B
lymphopoiesis. However, no single
model of human B cell development
has emerged as an initial standard for
subsequent refinement as it has for
the mouse. This has made it difficult
to compare results from different labo-
ratories and to fit published data into
a comprehensive model of human B
cell development that can be used to
compare B cell development at differ-
ent points in ontogeny.
The importance of equivalent tissue
sources in comparative studies of mu-
rine and human immunity is under-
scored by the recent identification of
a distinct B-1 cell progenitor that se-
lectively predominates during the fetal
period in the mouse (Montecino-
Rodriguez et al., 2006). Murine studies
that go back almost three decades
have identified B-1 (CD5+) and B-2
cells (CD5) as distinct B lymphocyte
subsets that perform complementary
immune functions (Hardy, 2006). B-1
cells predominate early in life, partici-
pate in T independent responses, and
generate polyreactive ‘‘natural’’ anti-
bodies that provide protection from
common bacterial pathogens. B-2
cells are the ‘‘conventional’’ B lympho-
cytes that form the majority of circulat-
ing B cells in the adult and give rise to
the diverse, highly specific, hypermu-
tated antibodies typically associated
with the adaptive immune response
and immunological memory. Murine
B-1 immunoglobulin specificities have
been described as relatively ‘‘hard-
wired.’’ They arise from the selective
use of a limited number of immuno-
globulin heavy-chain variable (IgH V)
gene segments. In addition, the mech-
anisms for generating diversity that
are present in conventional B-2 cells
(N nucleotide insertions and somatic
hypermutation) are either greatly re-
duced or absent in murine B-1 cells.
Whether humans produce distinct B
lymphocyte subsets that are function-
ally comparable to murine B-1 and
B-2 cells is unclear. In humans, CD5+ B
cells do predominate early in life—ap-
proximately 85% of B cells in umbilical
cord blood express CD5+, whereas the
absence of CD5 characterizes 85%
of the B cells in adult peripheral blood
(K.J.P. et al., unpublished data). How-
ever, the expression of CD5may not beier Inc.an indicator of B-1 cells in all species.
CD5+ and CD5 B cells are present in
pigs, but they do not give the B-1–B-2
functional dichotomy observed inmice
(Wilson and Wilkie, 2007). In addition,
CD5 can be upregulated during B cell
activation (Hardy, 2006), and there is
evidence to suggest that CD5 is tran-
siently expressed during post-BM
stages of human B cell development
(Sims et al., 2005). Thus, in humans,
CD5 may be a marker of B cell lineage,
B cell activation, and/or B cell devel-
opment.Clearly, experiments that seek
to identify and functionally assess
putative B-1 and B-2 cells in humans
will need to be designed to take into
account these possibilities.
Mechanisms that function in deter-
mining antibody specificities may also
vary between mice and humans. B-1
cells, if present in humans, may be
more diverse than those in mice be-
cause of terminal deoxynucleotide
transferase (TdT)-mediated, N nucleo-
tide additions during the immunoglob-
ulin gene-rearrangement process. In
humans, TdT is expressed in B cell de-
velopment during the fetal period and
throughout life. In contrast, the expres-
sion of TdT in mice is limited to adult B
lymphopoiesis. During IgH gene rear-
rangement in mice, B-1 cells selec-
tively incorporate V gene segments
from IgH families that are proximal to
the D and J segments, whereas B-2
cells use specificities encoded by dis-
tal IgH V gene segments (Hardy, 2006).
Whether differential V gene usage dis-
tinguishes CD5+ and CD5 B cells in
humans is controversial. Should IgH
V gene segments used in human B1
and B2 cells show structural similarity
to those in the mouse, the mecha-
nisms involved in specification of IgH
V gene usage are likely to be quite dif-
ferent. It is believed that most IgH V
gene segments arose from gene-
duplication events that occurred after
divergence of mice and humans,
including a fairly recent expansion of
the distal half of the murine IgH V gene
locus (de Bono et al., 2004). This is im-
portant because the V gene segments
that are selectively incorporated in
mouse B-2 cells, the V gene segments
that selectively require Ezh2-mediated
methylation of histone H3 for rear-
rangement, (Su et al., 2003), the V
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dergo STAT5-regulated histone H4
acetylation (Bertolino et al., 2005),
and the sites that direct nuclear com-
partmentalization (Yang et al., 2005)
are located in the distal portion of the
murine IgH V locus. Thus, divergent
genetic and epigenetic factors proba-
bly impact IgH V gene usage in mice
and humans.
Differences in mouse and human
centromeric DNAs suggest that there
may also be at least subtle variations
in epigenetic regulation between mice
and humans. Studies of the Ikaros
DNA-binding protein provide evidence
that this could impact mechanisms
that regulate gene expression in the
immune system. Pericentromeric het-
erochromatin in the mouse is relatively
homogeneous, including g satellite re-
peats with Ikaros binding sites at all
centromeres (Cobb et al., 2000). How-
ever, multiple unique centromeric
DNAs that vary from chromosome to
chromosome have been identified in
humans, and recent evidence sug-
gests that Ikaros is able to maintain
its regulatory function in humans
through mechanisms conferred by the
selective expression of a unique Ikaros
splice variant in human cells (Ronni
et al., 2007). This variation in the Ikaros
regulatory mechanism between mice
and humans is likely to be a factor in
B cell development because Ikaros
regulates expression of TdT and the
l5 component of the pre-B cell recep-
tor, molecules important in very early
stages of B lymphopoiesis.
Thus, critical comparisons between
the species require close attention to
many variables including those of on-
togeny, tissue of origin, and the poten-
tial limitations of both in vitro and
in vivo assays. Given the fairly obvious
risk in assuming that data can be ex-
trapolated from one species to an-other, it is surprising how rarely this
caveat is provided in presentations
and publications of data from murine
studies. A common tendency is to
view data from mice as ‘‘generic,’’
rather than specific, with the identity
of the species mentioned only in the
methods sections of published pa-
pers. Clearly, comprehensive models
of human lymphoid commitment and
differentiation are difficult to establish
given the experimental and logistical
obstacles. The elegant experimental
approaches available only for the anal-
ysis of murine biology will remain an
essential first step in the process of
understanding human systems. How-
ever, human models based on fine-
tuned definitions of surface-marker
expression during progressive stages
of ontogeny and in different tissues
will be essential tools to define the
mechanisms by which human lym-
phoid commitment and differentiation
is regulated.
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